Coronavirus (COVID-19) News
Filter News
Found 2,554 articles
-
The German biotech is trying to deepen its pipeline in cancer and other infectious diseases as COVID-19 markets contract and the international public health emergency comes to an end. -
Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug
5/3/2023
Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty'.
-
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
5/2/2023
Revive Therapeutics Ltd. announced that the independent Data and Safety Monitoring Board meeting of the Bucillamine Phase 3 clinical trial for COVID-19 is expected to convene on May 10th, 2023 and will assess the efficacy of Bucillamine in the Study’s Post-Dose selection data under the current Study’s protocol primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization.
-
Bioxytran Interview at the Emerging Growth Conference 2023
5/1/2023
BIOXYTRAN, INC. announced that Bioxtran CCO Michael Sheikh will be discussing the medical and scientific communities’ reaction to the latest peer reviewed journal article on the Emerging Growth Conference on May 3, 2023 at 12:35 pm EST.
-
Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
4/25/2023
Veristat congratulated HIPRA for marketing authorization by the European Medicines Agency and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age.
-
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
4/25/2023
NanoViricides, Inc. reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate.
-
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
4/17/2023
NanoViricides, Inc., a clinical stage global leader in nanomedicines against viruses, announced that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India.
-
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
4/12/2023
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status
-
At the World Vaccine Congress this week, Novavax presented data suggesting that its protein nanoparticle booster generated immune responses that could protect against severe infection. -
The FDA has granted emergency use authorization to InflaRx’s vilobelimab, now to be marketed as Gohibic, for hospitalized adult patients with COVID-19, the German biotech announced Tuesday. -
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
4/4/2023
Gritstone bio, Inc. announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases, taking place April 15-18, 2023 in Copenhagen, Denmark.
-
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
3/27/2023
YS Biopharma announced its positive interim Phase II safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine.
-
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea
3/27/2023
Biophytis SA announced that it has held a presentation on their drug candidate, Sarconeos, as a possibility to cure long COVID after hospitalization, at the 13th annual International Conference on Frailty and Sarcopenia Research.
-
The Rise, Fall and Future of Novavax
3/21/2023
On Feb. 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024. BioSpace takes a deep dive into the vaccine maker's prospects. -
First-of-Its-Kind Post-COVID-19 Panels Available at questhealth.com
3/21/2023
The consumer-initiated testing business from the leader in diagnostic testing, Quest Diagnostics, has introduced two innovative Post-COVID-19 panels.
-
Pregnancy Outcomes with COVID-19 Vaccines Reviewed in Journal of American Physicians and Surgeons (AAPS)
3/21/2023
The COVID-19 vaccine was developed and distributed with unprecedented speed, including to pregnant women.
-
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
3/21/2023
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus outbreak, the Company was granted an Emergency Use Authorization for its two-component recombinant COVID-19 vaccine ReCOV by Order No. A106 of the Minister of Public Health of Mongolia and a resolution of the Mongolian Committee for Medicinal Products for Human Use.
-
SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses
3/20/2023
SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from the Bill & Melinda Gates Foundation to further develop its novel SpyVector platform.
-
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
3/13/2023
ExeVir Bio announced the publication of a pre-print paper by De Cae et al., entitled “Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike”.
-
Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies
3/6/2023
Invivyd, Inc., a clinical stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announces the election of VYD222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19.